TNF Blockers Not Associated With Poorer Pregnancy Outcomes
Continuing a tumor necrosis factor inhibitor (TNFi) during pregnancy does not increase risk of worse fetal or obstetric outcomes, according to new research presented at the American College of Rheumatology (ACR) 2023 Annual Meeting. Patients who continued a TNFi also had fewer severe infections requiring hospitalization, compared with those who stopped taking the medication during …
